AAAAAA

   
Results: 1-10 |
Results: 10
Effect of P-30 protein and tamoxifen on transforming growth factor-beta 1 in patients with rising prostate specific antigen
Authors: Eid, JE Brunner, A Cummings, KB Weiss, RE Goodin, S Aisner, J Todd, M DiPaola, RS
Citation: Je. Eid et al., Effect of P-30 protein and tamoxifen on transforming growth factor-beta 1 in patients with rising prostate specific antigen, UROL ONCOL, 6(6), 2001, pp. 243-247
Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma
Authors: DiPaola, RS Chenven, ES Shih, WJ Lin, Y Amenta, P Goodin, S Shumate, A Capanna, T Cardiella, M Cummings, KB Aisner, J Todd, MB
Citation: Rs. Dipaola et al., Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma, CANCER, 92(8), 2001, pp. 2065-2071
Combined etoposide, ifosfamide, and cisplatin in the treatment of patientswith advanced thymoma and thymic carcinoma - An intergroup trial
Authors: Loehrer, PJ Jiroutek, M Aisner, S Aisner, J Green, M Thomas, CR Livingston, R Johnson, DH
Citation: Pj. Loehrer et al., Combined etoposide, ifosfamide, and cisplatin in the treatment of patientswith advanced thymoma and thymic carcinoma - An intergroup trial, CANCER, 91(11), 2001, pp. 2010-2015
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
Authors: Kaufman, D Raghavan, D Carducci, M Levine, EG Murphy, B Aisner, J Kuzel, T Nicol, S Oh, W Stadler, W
Citation: D. Kaufman et al., Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer, J CL ONCOL, 18(9), 2000, pp. 1921-1927
High-time chemotherapy or high time for low dose
Authors: Kamen, BA Rubin, E Aisner, J Glatstein, E
Citation: Ba. Kamen et al., High-time chemotherapy or high time for low dose, J CL ONCOL, 18(16), 2000, pp. 2935-2937
High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase IIstudy 9234
Authors: Vogelzang, NJ Herndon, JE Miller, A Strauss, G Clamon, G Stewart, FM Aisner, J Lyss, A Cooper, MR Suzuki, Y Green, MR
Citation: Nj. Vogelzang et al., High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase IIstudy 9234, ANN ONCOL, 10(5), 1999, pp. 597-600
Phase I trial, including pharmacokinetic and pharmacodynamic correlations,of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer
Authors: Belani, CP Kearns, CM Zuhowski, EG Erkmen, K Hiponia, D Zacharski, D Engstrom, C Ramanathan, RK Capozzoli, MJ Aisner, J Egorin, MJ
Citation: Cp. Belani et al., Phase I trial, including pharmacokinetic and pharmacodynamic correlations,of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer, J CL ONCOL, 17(2), 1999, pp. 676-684
Dose-response trial of megestrol acetate in advanced breast cancer: Cancerand leukemia group B phase III study 8741
Authors: Abrams, J Aisner, J Cirrincione, C Berry, DA Muss, HB Cooper, MR Henderson, IC Panasci, L Kirshner, J Ellerton, J Norton, L
Citation: J. Abrams et al., Dose-response trial of megestrol acetate in advanced breast cancer: Cancerand leukemia group B phase III study 8741, J CL ONCOL, 17(1), 1999, pp. 64-73
Overcoming bcl-2- and p53-mediated resistance in prostate cancer
Authors: DiPaola, RS Aisner, J
Citation: Rs. Dipaola et J. Aisner, Overcoming bcl-2- and p53-mediated resistance in prostate cancer, SEMIN ONCOL, 26(1), 1999, pp. 112-116
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission
Authors: Auperin, A Arriagada, R Pignon, JP Le Pechoux, C Gregor, A Stephens, RJ Kristjansen, PEG Johnson, BE Ueoka, H Wagner, H Aisner, J
Citation: A. Auperin et al., Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission, N ENG J MED, 341(7), 1999, pp. 476-484
Risultati: 1-10 |